Please assess the completion status of the following clinical trial:

Trial Title: Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age: 18 years and older~* Diagnosis of B-cell CLL by International Workshop on CLL (IWCLL) response criteria~* Relapsed CD23+ B-cell CLL~* Rai Stage III or IV, or Rai Stage I or II if determined to have disease progression as evidenced by rapid doubling or peripheral lymphocyte count, progressive lymphadenopathy, progressive splenomegaly, or B symptoms~* Prestudy WHO Performance Status less than or equal to 2~* Signed, written Institutional Review Board (IRB)-approved informed consent~* Men \& women of reproductive potential must agree to follow accepted birth control methods during treatment for 3 months after completion of treatment~* Acceptable liver function: Bilirubin less than or equal to 2.0 mg/dL (26 µmol/L), AST (SGOT) \&/or ALT (SGPT) less than or equal to 2 times upper limit of normal~* Acceptable hematologic status: Platelet count less than or equal to 50 x 10\^9/L, ANC less than or equal to 1 x 109/L~* Acceptable renal function: Serum creatinine less than or equal to 1.5 times upper limit of normal~Exclusion Criteria:~* Subjects who did not respond to prior FCR therapy (relapsed within 6 months of the last dose).~* Cancer radiotherapy, radioimmunotherapy, biological therapy, chemotherapy, or other investigational therapy within 4 weeks prior to Study Day 1~* Previous exposure to lumiliximab or other anti-CD23 antibodies~* Subjects who have had a prior allogenic bone marrow transplant (BMT) or autologous BMT or peripheral stem-cell transplant (PBSCT)~* Known infection with HIV, hepatitis B, or hepatitis C~* Uncontrolled diabetes mellitus~* Uncontrolled hypertension~* Transformation to aggressive B-cell malignancy (e.g., larger B-cell lymphoma, Richter's Syndrome, or prolymphocyte leukemia (PLL)~* Subjects with secondary malignancy requiring active treatment (except hormonal therapy)~* Subjects with medical conditions currently requiring long-term use (less than 1 month) of systemic corticosteroids~* Serious nonmalignant disease or laboratory abnormality, which, in the opinion of the investigator \&/or sponsor, would compromise protocol objectives~* Active uncontrolled bacteria, viral, or fungal infections~* New York Heart Association Class III or IV cardiac disease, myocardial infarction within the past 6 months prior to Study Day 1, unstable arrhythmia, or evidence of ischemia on ECG within 14 days prior to Study Day 1~* Seizure disorders requiring anticonvulsant therapy~* Severe chronic obstructive pulmonary disease with hypoxemia~* Major surgery, other than diagnostic surgery, within 4 weeks prior to Study Day 1~* Clinically active autoimmune disease~* Subjects with a history of fludarabine-induced autoimmune cytopenia~* Pregnant or currently breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).